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Background: Chronic neuropathic pain in thalamic pain syndrome remains intractable. Its poor response is
ascribed to destruction of the integrated neuromatrix in experience of pain. Deep brain stimulation is a promising
technique to modulate activity of implicated structures. However, traditional approaches targeting sensori-motor
substrates have failed to affect disability. The offending lesion in thalamic pain syndrome that almost invariably
destroys sensory pain pathways may render these classical approaches ineffective. Instead, we hypothesize that
targeting structures representing emotion and affective behavior-ventral striatum/anterior limb of the internal
capsule, may alleviate disability.
Methods/design: We present the design of our phase I randomized, double-blinded, sham-controlled, crossover
trial that examines safety, feasibility and efficacy of our proposed approach. In our ongoing trial, we intend to enroll
ten patients with thalamic pain syndrome. Following implantation, patients are randomized to receive active deep
brain stimulation to the ventral striatum/anterior limb of the internal capsule or sham for 3 months, after which
they are crossed over. The primary endpoint is Pain Disability Index. Other outcomes include visual analog scale,
depression and anxiety inventories, quality of life, and functional neuroimaging.
Discussion: Designing trials of deep brain stimulation for pain is challenging owing to the ethical-scientific
dilemma of introducing a control arm, complicated blinding, heterogeneous etiologies, patient expectations, and
inadequate assessment of disability. The quality of evidence in the field is classified as level III (poor) because it
mainly includes a multitude of uncontrolled case series reporting variable outcomes, with little regard for the
placebo effect related to implantation. Without valid data on efficacy, use of deep brain stimulation for pain
remains “off label”. We present our trial design to discuss feasibility of conducting sham-controlled phase I studies
that may represent significant refinement for the field. Double-blinding would reduce influence of patient
expectations and therapeutic confusion amongst investigators. With a cross-over approach, the dilemma regarding
including a control group can be mitigated. Use of homogeneous etiology, measurement of disability, depression
and quality of life, besides pain perception, all represent strategies to evaluate efficacy rigorously. Functional
imaging would serve to define mechanisms underlying observed effects and may help optimize future targeting.
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Thalamic pain syndrome: refractoriness to
traditional management
Chronic neuropathic pain, defined as ‘pain initiated or
caused by a primary lesion or dysfunction in the nervous
system’ [1], is one of the most prevalent disorders, affecting
about 8% of adults [2]. Although it can be associated with
peripheral or central pathology, pain of central origin, such
as that following stroke, is more resistant to treatment
[3-5]. In fact, pain associated with lesions of somatosensory
thalamic nuclei or somatosensory thalamo-cortical projec-
tions, following subcortical stroke, is particularly intractable
and extraordinarily frustrating for patients and physicians.
Also referred to as thalamic pain syndrome (TPS) or
Dejerine-Roussy syndrome, the disorder is characterized by
unrelenting pain, associated paradoxically with numbness
(anesthesia dolorosa) on the affected side. Its prevalence is
estimated to be 8% across all stroke patients but can be as
high as 18% in those with sensory deficits [6].
Poor responsiveness in TPS is attributed to disruption
of the pain neuromatrix [7]. The neuromatrix is an inte-
grated framework of somatosensory, limbic and cognitive
networks in the brain interacting with thalamo-cortical
pathways in the experience of pain. Since mechanisms of
pain in TPS span across such widespread cerebral struc-
tures within the neuromatrix, a promising technique in-
volves modulating activity of these structures with invasive
deep brain stimulation (DBS) [8].
Almost four decades ago [9] DBS was introduced to
target structures involved in pain transmission and opioid-
mediated analgesia, such as the periventricular and peria-
queductal gray matter. Fifteen years later, results continued
to be disappointing in TPS [4] even though response across
other etiologies was staggering. Emphasis was then shifted
to target the sensory thalamic nodes based on the premise
that stimulating the thalamus would inhibit hyperactivity
within pain-transmitting neuronal fibers associated with
unrelenting pain in TPS [10]. DBS of the ventral posterior
nuclei of the thalamus, however, generated inconsistent
benefit [4,5]. More recently, motor cortex stimulation
(MCS) was introduced as a less invasive alternative, based
on the hypothesis that motor cortical influence via cortico-
thalamic pathways would reduce thalamic hyperactivity in
pain [11]. Tsubokawa et al. initially demonstrated positive
results across several central pain syndromes [12], but
promise for patients with TPS was subsequently irreprodu-
cible [13-16]. Thus, it is critical to re-evaluate substrates
that have been targeted with DBS, to understand and re-
solve reasons for their failure in TPS over the last 40 years.
Importance of identifying novel nodes for targeting with
DBS in TPS
We suggest there may be several reasons for failure of
traditional DBS that targets sensorimotor substrates inmanagement of TPS. First, the offending lesion in TPS
damages sensorimotor targets such as the ventral-
posteromedial and ventral-posterolateral targets that are
critical to conduct the effects of contemporary DBS
[11,17]. Second, since pain experience and disability is
an integrative phenomenon of nociception influenced by
affect and cognition [7], substrates that are key for regu-
lation of emotion and behavior, such as ventral striatum
(VS) and anterior limb of the internal capsule (ALIC),
could be more effective in influencing the experience of
disability. Patients with TPS experience severe allodynia
and suffer from learned behaviors of anticipating pain,
which exacerbates disability. DBS that modulates VS/
ALIC may modify learned affective behavioral responses
[18] as in obsessive compulsive disorder [19] and de-
pression [20] and, thus, would potentially be more ef-
fective in mitigating pain-related disability.
Challenges in designing a clinical trial of DBS in
treatment of TPS
Our group has recently suggested departing from the
traditional approach of targeting DBS to sensorimotor
substrates and instead provided rationale for a novel
DBS target involving VS/ALIC in the management of
chronic neuropathic pain in TPS [21]. Examining effi-
cacy of a novel node of DBS in a population with refrac-
tory chronic neuropathic pain, however, is challenging
because the paradox of experience-subjectivity of pain
affects assessment of outcomes, while patient expecta-
tions from the investigational procedures as well as sur-
gical and neuro-stimulation interventions may generate
several confounds. The quality of contemporary evi-
dence regarding effectiveness of DBS in pain is currently
classified as level III because studies thus far, have en-
rolled heterogenous etiologies, incorporated inadequate
experimental blinding and controlled poorly for con-
founds of placebo. In addition, little regard has been
given to the risk for therapeutic confusion in the investi-
gative team about benefits of treatment, or to key out-
come measures that evaluate the experience/disability of
pain or its effect on quality of life, rather than severity
on a numerical scale of pain perception [8,22].
Objectives and hypothesis
Here, we present the protocol design of our current pilot
clinical trial where we examine: 1) safety and feasibility of
delivering DBS to VS/ALIC in a double blinded, random-
ized, sham-controlled, crossover clinical trial in patients
with TPS; 2) efficacy of the intervention with respect to
pain-related disability, quality of life, neuropsychological
and psychiatric outcomes and individual ratings of percep-
tion of pain; and 3) reorganization within affective net-
works of the pain neuromatrix with DBS delivered to VS/
ALIC, which will be studied using functional magnetic
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We hypothesize that DBS targeting VS/ALIC will modu-




A pilot, randomized, sham-controlled, double-blinded,
two-group crossover clinical trial design is being employed
to evaluate the safety and effectiveness of DBS targeting
VS/ALIC in TPS. Patients with TPS are being enrolled,
and then randomized to active DBS or sham following im-
plantation, after which they are crossed over. The study
has been approved by the Food and Drug Administration
with an Investigational Device Exemption as a phase I
clinical trial, and is registered (http://clinicaltrials.gov/ct2/
show/NCT01072656) as a clinical trial. The Institutional
Review Board of the Cleveland Clinic has approved the
study. Informed consent is obtained from all interested
participants in accordance with policies of the Board.
Patient population and recruitment
We are actively enrolling for this study. We intend to
enroll a total of 10 patients with TPS, such as that fol-
lowing stroke, surgical injury or focal traumatic injury,
proven refractory to conventional pain management.
The selection criteria are developed to enroll patients
with intractable pain contralateral to a brain lesion,
without severe psychiatric or cognitive comorbidities,
suicide ideation, major uncontrolled medical problems
or previous ablative surgery for TPS. Patients who have
had motor cortex stimulation (MCS) but not DBS are
also candidates, provided that the MCS hardware has
been removed. Inclusion and exclusion criteria are
discussed in detail below.
Inclusion criteria
 Age > 21 years
 Diagnosis of TPS >6 months
 MRI-confirmed lesion affecting the posterior
thalamus or dorsal or ventral vicinity of thalamus or
brain stem
 Patients with lesions involving the semi-oval white
matter in topography consistent with sensory
thalamo-cortical connections and presenting with
clinical syndrome consistent with TPS
 Chief complaints of intractable hemibody pain that
has remained at an average score >5 on the visual
analog scale (VAS, scores ranging between 0 and 10)
for 30 days, pinprick hypoesthesia over the affected
hemibody (anesthesia dolorosa), severe allodynia,
significant pain-related disability (Pain DisabilityIndex or PDI score >30), failure to respond to at
least one medication within each class of drugs
prescribed commonly for central pain syndrome,
including antidepressants, anti-seizure medications
and oral narcotics.Exclusion criteria
 Issues with psychiatric health, including inability to
cope with implantable hardware, severe
uncontrolled depression, bipolar disorder, severe
obsessive compulsive disorder, suicide ideation
within 12 months prior to enrollment or
communication of a plan should the investigational
treatment fail or imminent suicide risk (measured
based on the Montgomery-Asburg Depression
Rating Scale (MADRS) and the Columbia-Suicide
Severity Rating Scale (C-SSRS) and the Beck
Depression Inventory (BDI)
 Unstable physical health, other neurological lesions
or MRI-based incidental findings unrelated to the
offending lesion, women of childbearing age who are
pregnant at the time of enrollment or are not using
adequate contraception
 Co-morbidities including ongoing anticoagulation/
anti-aggregation therapy, uncontrolled hypertension
or major organ system failure
 Prior or concurrent therapies related to TPS,
including previous ablative intracranial surgery for
management of TPS, previous DBS therapy or
simultaneous enrollment in another clinical trial for
TPS
 Issues with cognitive health or ability to
communicate, such as inability to provide informed
consent, severe aphasia or inability to comply with
the logistical requirements of the research study
Patients are being recruited from the Cleveland Clinic
Neurological Institute Centers and from the Cleveland
Clinic Pain Management Center. Other institutions in
Northeastern Ohio and neighboring states have also
been contacted about the study. These centers have ac-
cess to the objectives of the study, intended population
and study criteria, but patients are only enrolled and
treated at the Cleveland Clinic.Study protocol: phases of the study
Phase I: screening and enrollment
Screening involves standard review of history, physical
and neurological examination, review of MRI within the
past year, pain questionnaires, psychiatric evaluation,
pain psychological evaluation and laboratory tests. Pa-
tients meeting selection criteria are enrolled.
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Phase II, or pre-operative baseline evaluation (Figure 1),
involves collection of several clinical outcome mea-
sures, including extensive neurological, neuropsycho-
logical pain and cognitive and psychiatric assessments
(Figure 1, Table 1). These assessments are performed
before implantation, and repeated during the random-
ized phase, and again during the open-label follow-
up phase. These evaluations are conducted by the
same specialized team that routinely assesses neuro-
logic, neuropsychological, cognitive and neuropsychi-
atric function in our clinical program and in our
research studies in DBS. Patients also undergo func-
tional neuroimaging (Figure 1).Figure 1 Study design. Flowchart of the study design based on specified
guidelines are marked on the right margin of the figure. *Time points whe
cognitive evaluations (Table 1) will be conducted. During phase V, fMRI and
randomized intervention allocation. During the open-label phase, follow-up
listed above and at month 12 and 24 for fMRI and MEG. TPS, thalamic pain
resonance imaging; MEG: magneto-encephalography; EuroQOL (EQ-5D), EuPhase III DBS implantation
All enrolled patients receive DBS implantation bilaterally
in the VS/ALIC target. DBS lead implantation is com-
pleted in the same fashion as previously described by our
group, but for the VS/ALIC target [18,24]. The VS/ALIC
is targeted approximately at its junction with the anterior
commissure and the electrodes are advanced further ven-
trally along the trajectory towards the VS. Once inserted,
intraoperative testing with macrostimulation through the
DBS lead is performed. Based on prior experience [20], we
have noted that the most ventral electrode contacts elicit
acute changes in mood or anxiety. At this stage, it is un-
known if stimulation also produces changes in pain per-
ception. If no effects are seen, the implanting team mayCONSORT clinical trial guidelines [23]. Categories defined in CONSORT
n neurological, neuropsychological pain or neuropsychological
MEG evaluations will be conducted at 2 and 5 months after
assessments are conducted at month 9, 12, 18 and 24 for outcomes
syndrome; DBS, deep brain stimulation; fMRI: functional magnetic
ro Quality of Life scale.




Sensory and motor systems
Neuropsychological
Pain Evaluation:






a) California Verbal Learning Test
b) Wechsler memory Scale
c) Delis-Kaplan Executive Function System
d) Wisconsin Card Sorting Test
e) Beck Depression Inventory
f) Beck Anxiety Inventory
g) Columbia Suicide Severity Rating Scale (CSSRS)
h) Montgomery-Asburg Depression Rating Scale
(MADRS)
i) Twenty Item Positive and Negative Affect
Schedule (PANAS) and NEO Five Factor Inventory
(NEO_FFI)
Neurological, neuropsychological pain and neuropsychological cognitive and
psychiatric examinations; marked by an asterisk in Figure 1, these
examinations will be conducted at pre-operative baseline, at the time of
randomization and at month 12 and 24 following randomization (well into
phase VI follow-up testing).
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is identified, DBS leads are anchored to the skull and surgi-
cal sites are closed. The implantable pulse generator (IPG)
is positioned in the infraclavicular area and connected to
DBS leads under general anesthesia. Since the surgical
intervention and general anesthesia may be a risk for cogni-
tive decline, we serially assess cognitive function to note
whether any patients experience negative effects on cogni-
tion related to our interventions (see Table 1).
Phase IV: DBS programming and titration
DBS programming is initiated at least a month after DBS
surgery to allow for resolution of microlesional effects. In
acute programming, patients are asked to report changes
in mood, anxiety, pain or suffering with activation of one
or more electrode contacts. If the affective reporting of
pain is not influenced, then settings affecting mood and
anxiety can be chosen for chronic stimulation. All stimula-
tion settings are planned below a charge density of 30 μC/
cm2/phase, using the formula:
Charge density μC=cm2=phase
 
¼ Voltage Vð Þ  Pulse width μsð Þ
Lead surface area cm2ð Þ  Impedance Ωð Þ Eq: 1
Phase V: randomization and intervention
Once optimal settings are determined, stimulation is
turned off for about a month in order to minimize the ef-
fects of experience and memory of stimulation. Patients
are then randomized to either the DBS group that receivesactive stimulation programmed to the settings found to be
optimal during titration in phase IV, or to the sham group
that receives 0 V (no electrical current) stimulation. As a
technical detail, for minimizing risk to blinding pro-
cedures, the pulse generator is always kept on during all
phases so that if any patients have tests that could indicate
the status of the generator, it will always appear to be
turned on Patients are randomized in a 1:1 ratio to one of
the two groups.
Phase VI: open-label phase
Upon completion of the third month post-crossover, all pa-
tients are reprogrammed to the optimized stimulation set-
tings, as deemed necessary by the investigators at that time
to maximize clinical benefits. There is no sham stimulation
after this point. The goal is to reduce pain-related disability.
Follow-up assessment of outcomes is conducted at month
9, 12, 18 and 24.
Endpoints of safety
Risks can be related to the procedures for implantation of
DBS hardware, or the stimulation of the target area. Add-
itional risks could be related to conducting MRI with im-
planted DBS. Events or instances that can present as risks
are noted in detail in Table 2. Clinical experience of the re-
search team, pre-operative image guidance, prophylactic
antibiotics, and preparatory laboratory work is critical in
mitigating risks related to DBS and implantation. Risks of
stimulation are mitigated by choosing settings below the
threshold for intolerable side effects [19]. Risk for suicidal
ideation is monitored throughout the trial using C-SSRS.
The protocol is outlined such that if serious signs are
detected, psychiatric assessment will promptly follow. If the
risk remains high for more than 28 days or if two or more
events of imminent risk are recorded, then the individual
will be removed from the blinded phase of the study.
Feasibility of blinding
Our current trial is a double-blinded study where nei-
ther patients nor investigators performing outcome as-
sessments know whether DBS or sham is delivered.
Maintaining a blinded study is important because of
the subjective nature of reports of pain and disability.
Loss of blinding may occur due to the magnitude of the
therapeutic effect or any other subjective perception
that indicates that active DBS or sham is delivered.
Safeguards have been incorporated to prevent loss of
experimental blinding; for instance, stimulation is
turned to 0 V after the programming and titration in
phase IV to minimize the chance of memory of stimu-
lation affecting the patient’s perception of receiving ac-
tive DBS or sham in blinded phase V. In addition,
patients and blinded investigators are asked separately
via questionnaire, what they believe is the status of the
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we will evaluate how effective the blinding strategy was
in order to guide us forward.Outcomes of efficacy
Outcomes of pain, pain-related suffering and disability,
depression and anxiety, functional status, motor abil-
ities, and suicidal ideation are collected at several time
points (Figure 1).Primary endpoint
Instead of using the historically accepted criterion of
50% analgesia (using the VAS), we instead chose a 40%
effect on the PDI as our primary endpoint. The PDI
measures disability in physical and psychosocial categor-
ies spanning across domains such as family, sexual, so-
cial, recreational, self-care, occupational and life-support
domains [25]. Its strong relationship with quality of life
outcomes makes it equivalent and potentially superior to
existing functional-status questionnaires used in pain re-
search, such as the VAS [26].Secondary endpoints
Secondary endpoints include: 1) 40% improvement in
PDI in 50% of patients at 2-year follow up; 2) affirmative
response to the prospect of receiving the treatment again
if the same outcome were to be achieved; and 3) 50% re-
duction in VAS at 2-year follow up.
Other outcomes include neuropsychological pain, and
cognitive and psychiatric assessments (Figure 1, Table 1)
as follows:Table 2 Overall risks of the study across various categories
Category of Risks Specific Risks
Risks of DBS surgery and
Implantation of Pulse Generator
Intracerebral hemorrhage; infection
operative displacement of leads; re
intracranial extra-axial hemorrhage;
hardware; hardware problems, such
cerebrospinal fluid leak; seroma; co
IPG; injury along the tunneling traje
(severe injury, cognitive decline, an
Risks Pertaining to Hardware
Maintenance
Migration; infection; hardware malf
implants; erosion; incompatibility w
diagnostic devices
Risks due to stimulation and
conduct of the experiment
Stroke/brain hemorrhage; dizziness
voluntary movements; numbness; a
and imminent risk of suicide (based
interview); hypomania or motor co
chronic pain condition; behavioral
stopped; visual field defects or eye
psychiatric problems; changes in se
events; electromagnetic interferenc
Risks Involved with Imaging MRI may cause lesion to region tar
IPG, implantable pulse generator; MADRS, Montgomery-Asburg Depression Rating S
Inventory; MRI, Magnetic Resonance Imaging. The McGill Pain Questionnaire consists of
descriptors of pain, including sensory, affective,
evaluative and miscellaneous categories [27]
 The Beck Depression and Anxiety Inventories are
self-report measures to document the level of
depression [28] and anxiety and have been used in
DBS studies of chronic neuropathic pain [5]
 Tests of manual dexterity: the box and block test
specifically measures the grasp and release function
of the paretic hand.
 EuroQOL (EQ-5D VAS) is a measure of health-
related quality of life that has been employed in
previous DBS studies in neuropathic pain [29]
 C-SSRS [30] provides valid, sensitive and specific
assessment of suicidal ideation and behavior
 MADRS is a valid, acceptable, reliable and sensitive
patient-reported outcome assessing severity of
depression [31]
 Neuropsychological tests of cognitive function will
include the California Verbal Learning Test, the
Wechsler memory Scale, the Delis-Kaplan Executive
Function System and the Wisconsin Card Sorting
Test
In functional neuroimaging, fMRI and MEG are utilized
to help define affective-cognitive networks associated with
allodynia and anticipation of pain in chronic TPS, and
their potential modulation with DBS of the VS/ALIC;
fMRI has been performed safely in patients with DBS im-
plants in our previous studies [32]. Our group has demon-
strated that DBS delivered specifically to the VS/ALIC is
associated with cortical-subcortical fMRI activation that
represents affective networks in the brain [32]. MEG useabscess; meningitis; misplacement of leads requiring revisions; post-
action to lead materials; hypodensity with mass effect around lead;
stroke; pain at site of surgery; migration of leads; erosion of skin over
as abnormal impedances; hydrocephalus; seizures/epilepsy;
llection formation; pneumothorax/hemothorax/pleural effusions due to
ctory in the region of head, neck or chest; risks related to anesthesia
d death)
unction/break; insulation problems; leaks of electricity; reaction to
ith MRIs; incompatibility with surgical equipment, medical devices or
; dyspraxia, dystonia, facial and limb muscle weakness, abnormal
ttention, memory or language processing difficulties; suicide ideation
on MADRS’ item 10, CSSRS’ item 5, BDI’s item 9 and behavioral
ntractions; any other unanticipated neurological deficits; worsening of
or cognitive changes; rebound of symptoms when stimulation is
movement disorders; headache; abnormal thinking; behavioral or
xual function; disorders of consciousness; cardiovascular or respiratory
e; MRI may damage implantable devices
geted by DBS; fatigue and discomfort associated with nociceptive stimuli
cale; C-SSRS, Columbia Suicide Severity Rating Scale; BDI, Beck Depression
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feasible [33,34]. We chose to utilize both fMRI and MEG
to reveal substrates of affective dimension of pain because
their unique strengths are complementary. Whereas fMRI
is associated with superior spatial resolution, MEG pos-
sesses very high temporal resolution [35].
Both MEG and fMRI are exploratory in this study.
With fMRI, one of our goals is to evaluate resting state
fMRI, comparing networks when DBS is turned on
versus when it is turned off. Patients will undergo
resting-state fMRI at pre-operative baseline, during the
randomized blinded phase and during follow up. Thus,
by comparing the DBS-on and DBS-off conditions, we
will be able to assess the effects of active versus sham
DBS without confounds related to placebo or study-
related effects. The next goal is to correlate changes in
the neural networks related to the placebo effect; we in-
tend to do so by comparing effects of DBS-off stimula-
tion between active, sham and pre-operative baseline
phases. With MEG, we aim to harness its high temporal
resolution to assess possible effects of DBS on pain an-
ticipation. The primary hypothesis is that DBS will have
a significant effect upon the affective sphere of chronic
pain. Pain anticipation is one of the conditions leading
to pain habituation and chronic pain. Thus, we theorize
that improvements in the affective sphere will also be
correlated to how cortical networks in patients with TPS
modulate in pain anticipation. In order to test this con-
cept, we have created a visual paradigm of pain anticipa-
tion that consists of a simple, three-second countdown.
The type of visual paradigm encodes whether or not a
painful stimulus would follow the countdown. One of
the limitations related to this paradigm is that we do not
have a full characterization of how healthy individuals
respond to pain anticipation in this task. This can limit
our understanding of how processing of pain anticipa-
tion is abnormal in individuals with TPS, and could as
well limit the interpretation of effects of active DBS. In
order to address these limitations, we are also evaluating
a cohort of 10 healthy subjects to allow comparisons.
Statistical and data analysis plan
Safety and feasibility
The goal of this study is to evaluate the safety and feasibil-
ity of delivering DBS to the VS/ALIC in patients with TPS
in a double-blinded, randomized, sham-controlled, cross-
over clinical trial. A Data Safety and Monitoring Board
(DSMB) has been established as an advisory group to
evaluate adverse events and judge overall integrity and
conduct of the study. DSMB review at the outset, half-
way through the enrollment process and at the end, will
record numbers of participants enrolled, participants
lost to follow up, deviations from protocol, threats to
blinding and adverse events, following which, decisionsabout continuation or recommendations for changing
or ending the study could be made.
If DBS is acutely and significantly effective in patients
who are randomized to receive DBS of the VS/ALIC first,
then there is a chance that patients may notice substantial
worsening of the pain (assuming that the intervention is
effective) and the validity of the experimental blinding
may be compromised. In this case, to investigate the effect
on blinding, we will record the patient’s and the blinded
investigator’s subjective perception (to the best of their
ability to guess) of whether active DBS or sham was being
delivered during the blinded phase. If the relapse in pain is
considered to be threatening or if there is suicidal ideation,
then stimulation will be re-initiated and/or patient will be
allowed to escape randomization [20,36]. On the other
hand, if patients receive sham stimulation first, a relapse
in pain will be managed with medical management at that
time, because we do not anticipate much change in their
baseline pain.
Sample size estimation and efficacy
Since the study is designed as a randomized, sham-
controlled, double-blinded study, we will also be able to
evaluate whether any potential trend indicates efficacy,
which would help compute effect sizes and variance in
DBS versus sham phases to estimate sample sizes for
adequate power in future. Our within-subject, crossover
design would also yield the magnitude of placebo effect
related to the surgical process itself that is an important
practical issue to consider in effect-size estimates for
the future.
This study was initially planned to involve a total of 34
patients. The sample size was estimated based on
changes in PDI in patients with central pain syndrome
in an earlier study [37]. It was determined that to detect
an effect size of 0.5 (equivalent to a 7-point decrease in
PDI), a total of 34 patients would need to have been in-
cluded for statistical power of 80% on a two-sided test
with a type I error probability of 0.05. The Food and
Drug Administration of the United States has, however,
determined in its review that the study should initially
enroll 10 patients as part of a phase I, safety study.
Due to the small sample size of the proposed pilot
phase I trial, procedures for corrections for multiple
comparisons cannot be instated; the scope of the subse-
quent phase II trial would be better suited to include
such procedures. By examining only a priori hypotheses,
we aim to mitigate the probability of making type I er-
rors. Therefore, we will compare the differences in the
primary and secondary outcomes in the third month of
DBS with those in the third month of sham stimulation
using the paired t-test at α = 0.05. Despite the sample
size limitation, we expect the study to be informative in
estimating the magnitude of the placebo effect after
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date are unknown. These will be valuable in designing
subsequent phase II and III studies.
Discussion and conclusions
Our protocol aims to test the safety, feasibility and
preliminary efficacy of a novel, neuromodulation ther-
apy for intractable TPS. Our approach is based on the
premise that failure of traditional cerebral neuro-
modulation in TPS with DBS [4,5,13,16] emerges from
over-reliance on modifying the percept of pain by
stimulating sensory-discriminative substrates that may
be unviable owing to the offending lesions. Further,
since the affective component of pain experience is
equally, if not more important than the perceived in-
tensity of pain, targeting regions such as VS/ALIC may
successfully modify pain experience without necessarily
modifying perception of pain intensity. The level of evi-
dence, however, supporting efficacy for DBS in chronic
neuropathic pain is mainly considered class III (de-
scriptive case series, unblinded designs) [38], attributed
to poor control of confounders of therapeutic benefit of
neuromodulation. While addressing our research ques-
tion, we have built study design refinements to poten-
tially inform current and future clinical DBS trials in
the field.
The ethical-scientific dilemma of introducing a control
arm is particularly intense in neurosurgery, given the
risk of interventions to the brain. However, since DBS
allows for all patients to be implanted at first and then
be randomized to active stimulation or sham, studies
have explored randomized controlled designs in the use
of DBS, particularly in movement disorders [39-42].
Thus, to balance ethical issues (potentially effective
treatment compared against control or less effective
treatment) with the importance of generating rigorous
empirical evidence, we have incorporated a randomized,
controlled, crossover design, where both active DBS and
sham groups switch to the other intervention after 3
months from their initial randomization. That thera-
peutic benefits may carry over from the DBS into the
sham phase cannot be completely discounted. By evalu-
ating outcomes between active DBS and sham in the
third month of corresponding treatments, we expect to
minimize the influence of carry over; by noting differ-
ence in outcomes between the third month of the initial
treatment and the first month of the intervention after
crossover, we may also be able to define an adequate
time lapse for future crossover studies.
Despite the inclusion of a placebo-controlled phase,
altogether, patient expectations from undergoing a
clinical-like investigational DBS procedure, the-
rapeutic confusion within the investigative team,
and unintentional cues during programming, canintroduce several unwanted influences in clinical
trial design. By introducing blinding for patients and
employing a team where the investigator collecting out-
come data is blinded and the surgeon and programming
physicians are unaware of outcomes during the blinded
phase, we aim to minimize unintentional cues and en-
sure investigator equipoise [22]. We are also minimizing
unintentional cues by allowing adequate time (approxi-
mately 1 month) to elapse between programming for DBS
and randomization to the intervention group, so that
memory of the experience of stimulation is reduced.
Nevertheless, a caveat exists. The therapeutic effects may
influence patients’ perceptions, and thus, the integrity of
experimental blinding [42]. For instance, early effects on
mood and anxiety may inflate perceived benefits. To study
this possibility, we will document the frequency with
which patients can guess the allocated treatment and we
will relate the Beck depression and anxiety inventories
with PDI to note whether the placebo of DBS confounds
therapeutic differences from the sham. We acknowledge,
however, that small sample size may limit our ability to
draw concrete inferences.
Finally, to allow systematic study of efficacy, adequate
controls in enrollment and analysis would be critical.
We are maintaining diagnostic consistency by restricting
inclusion only to TPS etiology. Although such a step
limits the sample size, it addresses the criticism of previ-
ous DBS studies where heterogeneity of etiologies and tar-
gets affected concrete conclusions about therapeutic
efficacy [8]. With regards to analysis, instead of using the
typical 50% response on the VAS as the success criterion,
we base our choice of outcomes upon the intended thera-
peutic benefit. Because the affective experience of pain, ra-
ther than pain intensity itself, may be influenced with DBS
of VS/ALIC, the Pain Disability Index has been chosen in-
stead, and a success criterion with this measure has been
defined at 40%. Since we anticipate a relation between
affective and cognitive benefits and alleviation of pain dis-
ability, detailed neuropsychological pain, and cognitive
and psychiatric assessments are explored to study interac-
tions between pain, mood, anxiety, and depression, as well
as personality and memory/experience, and the overall ef-
fect on quality of life. Long-term follow-up time points
have been built into the design to allow calculation of
long-term efficacy or stimulation tolerance. Last, our pilot
study also represents the first attempt at investigating the
proof-of-mechanism of a novel target of neuromodulation
in TPS so that the influence of such targeting on pain net-
works can be described.
The benefits of DBS in chronic neuropathic pain,
especially in TPS, are still less than adequate, to justify
approval for widespread clinically labeled use. We pro-
pose that identifying better clinical alternatives in DBS
may potentially improve efficacy of the approach. More
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http://www.trialsjournal.com/content/14/1/241importantly, however, it is incumbent on the field to in-
corporate well-controlled, blinded trial designs to ex-
plore the benefits of current as well as novel DBS
targets. Based on recent recommendations, our trial in-
volving DBS of the VS/ALIC may serve as an example
of feasibly creating protocols that improve the quality of
the evidence base.
Trial status
The trial is ongoing and is actively enrolling.
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